BioMarin is pumping the brakes on yet another indication for its CNP analogue, Voxzogo. | The rare disease biotech announced ...
In a push to free itself up for more R&D, Sanofi is acquiring a stake in German drugmaker, Cheplapharm. | In a deal that ...
The agreement makes AbbVie, which reported $3.2 billion in neuroscience sales in the second quarter, the official pharmaceutical sponsor of the PGA Tour, a professional golf organization. This month’s ...
“In healthcare communications, memorability is what helps turn awareness into action,” Pooja Bhavsar, SVP, strategic planner at The Bloc, said in a statement. “Make the Call was designed to be ...
The FDA has approved the industry’s very first generic radioligand therapy, known as a radioligand equivalent. | The FDA has approved the industry’s first radioligand equivalent in Curium’s lutetium ...
In what signifies the end of a challenging regulatory journey, Scholar Rock secured an FDA approval for its spinal muscular ...
GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk. | GSK is ...
Commercial strategies are often developed months before execution, but today's life sciences environment rarely stands still.
Biopharma innovation is moving fast, yet according to Ryan Keeling, CEO of Diaceutics, the industry continues to face a ...
GSK is advancing its inaugural lung cancer asset, Jideytro, toward a landmark first-line FDA approval, aided by an ...
A higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ...
Akeso and Summit Therapeutics’ ivonescimab reduced the risk of death by 27% compared with Keytruda in patients with treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results